S. Ingate

发表

THE ASYMMETRIC PAUSON-KHAND REACTION. A REVIEW

S. Ingate, J. Marco-Contellers, 1998 .

Web-Based Patient-Reported Outcomes in Drug Safety and Risk Management

A. Banerjee, S. Ingate, 2012, Drug Safety.

Studies into the synthesis of derivatives of 4-amino-2,3-dihydroisothiazole 1,1-dioxides and 4-amino-1,2-oxathiole 2,2-dioxides: The search for linked π-system containing analogues as potential inhibitors of HIV-1 reverse transcriptase

E. Clercq, M. Witvrouw, J. Marco, 1997 .

Post-Approval Evaluation of Effectiveness of Risk Minimisation: Methods, Challenges and Interpretation

A. Banerjee, Stella Wooder, S. Ingate, 2014, Drug Safety.

An Industry Perspective on the Erice Declaration and Risk Minimisation Plans

A. Banerjee, S. Ingate, D. Tranter, 2006, Drug safety.

Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors.

E. De Clercq, J. Balzarini, M. Witvrouw, 1999, Bioorganic & medicinal chemistry.

From α,α-disubstituted α-aminonitriles to heterocycles: Synthesis of derivatives of 4-amino-2,3-dihydroisothiazole 1,1-dioxide, a new heterocyclic ring system

J. Marco, S. Ingate, 1997 .

Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication.

E. De Clercq, C. Pannecouque, J. Balzarini, 1998, Journal of medicinal chemistry.

Synthesis and anti-HIV-1 Activity of [1-[2′,5′-Bis-O-(Tert-Butyldimethylsilyl)-β-L-Ribofuranosyl]Thymine]-3′-Spiro-5″-(4″-Amino-1″,2″-Oxathiole-2″,2″-Dioxide) (L-TSAO-T), the L-enantiomer of the Highly Specific HIV-1 Reverse Transcriptase Inhibitor TSAO-T

E. De Clercq, J. Balzarini, M. Camarasa, 1995 .

Novel L-lyxo and 5'-deoxy-5'-modified TSAO-T analogs: synthesis and anti-HIV-1 activity.

E. De Clercq, J. Balzarini, M. Camarasa, 1996, Antiviral research.

Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2'- and 5'-positions of the sugar moiety.

E. De Clercq, J. Balzarini, M. Camarasa, 1995, Antiviral research.

TSAO DERIVATIVES: HIGHLY SPECIFIC INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) REPLICATION

J. Balzarini, E. Clercq, A. Karlsson, 1995 .

The CSIC Reaction on Substrates Derived From Aldehydes

J. Marco, C. Jaime, S. Ingate, 2000 .

New and unexpected developments of the carbanion-mediated sulfonate (sulfonamide) intramolecular cyclization reaction (CSIC reaction)

J. Marco, S. Ingate, Pilar Manzano, 1998 .

Synthesis of [1-[2′,5′-bis-O-(t-Butyldimethylsilyl)-β- L-ribofuranosyl] thymine]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) (L-TSAO-T)

J. Balzarini, E. Clercq, S. Ingate, 1995 .

1,1,3-Trioxo-2H,4H-Thieno[3,4-e][1,2,4]Thiadiazine (TTD) Derivatives: a New Class of Nonnucleoside Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitors with Anti-HIV-1 Activity

R. Esnouf, E. De Clercq, C. Pannecouque, 1998, Antimicrobial Agents and Chemotherapy.

The CSIC [Carbanion mediated Sulfonate (Sulfonamido) Intramolecular Cyclization] reaction: Scope and limitations

J. Marco, S. Ingate, P. M. Chinchón, 1999 .

New and Unexpected Developments of the Carbanion‐Mediated Sulfonate (Sulfonamide) Intramolecular Cyclization Reaction (CSIC Reaction).

J. Macro, S. Ingate, Pilar Manzano, 1998 .